SCHOTT PHARMA AG& CO KGAA (1SXP.DE) Stock Fundamental Analysis
FRA:1SXP - Deutsche Boerse Ag - DE000A3ENQ51 - Common Stock - Currency: EUR
1SXP gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 15 industry peers in the Life Sciences Tools & Services industry. 1SXP has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. 1SXP is valied quite expensively at the moment, while it does show a decent growth rate. With these ratings, 1SXP could be worth investigating further for quality investing!.
1. Profitability
1.1 Basic Checks
1SXP had positive earnings in the past year.
In the past year 1SXP had a positive cash flow from operations.
In the past 5 years 1SXP has always been profitable.
In the past 5 years 1SXP always reported a positive cash flow from operatings.
1.2 Ratios
1SXP has a Return On Assets of 9.07%. This is amongst the best in the industry. 1SXP outperforms 100.00% of its industry peers.
The Return On Equity of 1SXP (16.17%) is better than 100.00% of its industry peers.
1SXP has a better Return On Invested Capital (12.56%) than 100.00% of its industry peers.
1SXP had an Average Return On Invested Capital over the past 3 years of 15.68%. This is significantly above the industry average of 6.90%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.07% | ||
| ROE | 16.17% | ||
| ROIC | 12.56% |
ROA(3y)11.06%
ROA(5y)11.96%
ROE(3y)19.55%
ROE(5y)21.48%
ROIC(3y)15.68%
ROIC(5y)17.03%
1.3 Margins
1SXP has a Profit Margin of 14.05%. This is amongst the best in the industry. 1SXP outperforms 86.67% of its industry peers.
In the last couple of years the Profit Margin of 1SXP has remained more or less at the same level.
With a decent Operating Margin value of 16.77%, 1SXP is doing good in the industry, outperforming 80.00% of the companies in the same industry.
1SXP's Operating Margin has improved in the last couple of years.
Looking at the Gross Margin, with a value of 33.04%, 1SXP is in line with its industry, outperforming 46.67% of the companies in the same industry.
1SXP's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 16.77% | ||
| PM (TTM) | 14.05% | ||
| GM | 33.04% |
OM growth 3Y3.98%
OM growth 5YN/A
PM growth 3Y0.22%
PM growth 5YN/A
GM growth 3Y-1.12%
GM growth 5YN/A
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), 1SXP is creating value.
Compared to 1 year ago, 1SXP has about the same amount of shares outstanding.
The debt/assets ratio for 1SXP is higher compared to a year ago.
2.2 Solvency
1SXP has an Altman-Z score of 4.89. This indicates that 1SXP is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 4.89, 1SXP belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
The Debt to FCF ratio of 1SXP is 2.00, which is an excellent value as it means it would take 1SXP, only 2.00 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 2.00, 1SXP belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
1SXP has a Debt/Equity ratio of 0.10. This is a healthy value indicating a solid balance between debt and equity.
1SXP has a better Debt to Equity ratio (0.10) than 100.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.1 | ||
| Debt/FCF | 2 | ||
| Altman-Z | 4.89 |
ROIC/WACC1.68
WACC7.46%
2.3 Liquidity
1SXP has a Current Ratio of 1.40. This is a normal value and indicates that 1SXP is financially healthy and should not expect problems in meeting its short term obligations.
1SXP's Current ratio of 1.40 is in line compared to the rest of the industry. 1SXP outperforms 46.67% of its industry peers.
A Quick Ratio of 1.06 indicates that 1SXP should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.06, 1SXP is in line with its industry, outperforming 46.67% of the companies in the same industry.
1SXP does not score too well on the current and quick ratio evaluation. However, as it has excellent solvency and profitability, these ratios do not necessarly indicate liquidity issues and need to be evaluated against the specifics of the business.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.4 | ||
| Quick Ratio | 1.06 |
3. Growth
3.1 Past
1SXP shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -1.43%.
Measured over the past years, 1SXP shows a quite strong growth in Earnings Per Share. The EPS has been growing by 14.04% on average per year.
The Revenue has been growing slightly by 6.51% in the past year.
Measured over the past years, 1SXP shows a quite strong growth in Revenue. The Revenue has been growing by 13.84% on average per year.
EPS 1Y (TTM)-1.43%
EPS 3Y14.04%
EPS 5YN/A
EPS Q2Q%-34.48%
Revenue 1Y (TTM)6.51%
Revenue growth 3Y13.84%
Revenue growth 5YN/A
Sales Q2Q%-1.04%
3.2 Future
The Earnings Per Share is expected to grow by 11.46% on average over the next years. This is quite good.
1SXP is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 8.44% yearly.
EPS Next Y4.94%
EPS Next 2Y12.5%
EPS Next 3Y13.4%
EPS Next 5Y11.46%
Revenue Next Year5.65%
Revenue Next 2Y8.73%
Revenue Next 3Y9.21%
Revenue Next 5Y8.44%
3.3 Evolution
The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 26.63 indicates a quite expensive valuation of 1SXP.
Based on the Price/Earnings ratio, 1SXP is valued a bit cheaper than 66.67% of the companies in the same industry.
1SXP's Price/Earnings ratio indicates a similar valuation than the S&P500 average which is at 28.79.
With a Price/Forward Earnings ratio of 18.91, 1SXP is valued on the expensive side.
1SXP's Price/Forward Earnings ratio is in line with the industry average.
1SXP is valuated at similar levels of the S&P average when we compare the Price/Forward Earnings ratio to 21.38, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 26.63 | ||
| Fwd PE | 18.91 |
4.2 Price Multiples
The rest of the industry has a similar Enterprise Value to EBITDA ratio as 1SXP.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of 1SXP indicates a slightly more expensive valuation: 1SXP is more expensive than 73.33% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 78.03 | ||
| EV/EBITDA | 15.79 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
1SXP has an outstanding profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as 1SXP's earnings are expected to grow with 13.40% in the coming years.
PEG (NY)5.39
PEG (5Y)N/A
EPS Next 2Y12.5%
EPS Next 3Y13.4%
5. Dividend
5.1 Amount
1SXP has a yearly dividend return of 0.68%, which is pretty low.
1SXP's Dividend Yield is a higher than the industry average which is at 0.92.
With a Dividend Yield of 0.68, 1SXP pays less dividend than the S&P500 average, which is at 2.51.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.68% |
5.2 History
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
1SXP pays out 16.84% of its income as dividend. This is a sustainable payout ratio.
DP16.84%
EPS Next 2Y12.5%
EPS Next 3Y13.4%
FRA:1SXP (4/25/2025, 7:00:00 PM)
23.7
+0.1 (+0.42%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners18.96%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap3.57B
Analysts74.74
Price Target28.98 (22.28%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.68% |
Yearly Dividend0.15
Dividend Growth(5Y)N/A
DP16.84%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-12.71%
Min EPS beat(2)-14.42%
Max EPS beat(2)-10.99%
EPS beat(4)1
Avg EPS beat(4)1.19%
Min EPS beat(4)-20.63%
Max EPS beat(4)50.83%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-4.16%
Min Revenue beat(2)-5.31%
Max Revenue beat(2)-3%
Revenue beat(4)1
Avg Revenue beat(4)0.16%
Min Revenue beat(4)-5.31%
Max Revenue beat(4)11.1%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)4.39%
PT rev (3m)-8.38%
EPS NQ rev (1m)0.14%
EPS NQ rev (3m)-14.6%
EPS NY rev (1m)-1.6%
EPS NY rev (3m)-8.07%
Revenue NQ rev (1m)-1.1%
Revenue NQ rev (3m)-6.72%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.86%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 26.63 | ||
| Fwd PE | 18.91 | ||
| P/S | 3.74 | ||
| P/FCF | 78.03 | ||
| P/OCF | 19.43 | ||
| P/B | 4.3 | ||
| P/tB | 4.47 | ||
| EV/EBITDA | 15.79 |
EPS(TTM)0.89
EY3.76%
EPS(NY)1.25
Fwd EY5.29%
FCF(TTM)0.3
FCFY1.28%
OCF(TTM)1.22
OCFY5.15%
SpS6.34
BVpS5.51
TBVpS5.3
PEG (NY)5.39
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.07% | ||
| ROE | 16.17% | ||
| ROCE | 15.36% | ||
| ROIC | 12.56% | ||
| ROICexc | 12.85% | ||
| ROICexgc | 13.25% | ||
| OM | 16.77% | ||
| PM (TTM) | 14.05% | ||
| GM | 33.04% | ||
| FCFM | 4.79% |
ROA(3y)11.06%
ROA(5y)11.96%
ROE(3y)19.55%
ROE(5y)21.48%
ROIC(3y)15.68%
ROIC(5y)17.03%
ROICexc(3y)16.18%
ROICexc(5y)17.77%
ROICexgc(3y)16.78%
ROICexgc(5y)18.78%
ROCE(3y)19.2%
ROCE(5y)20.87%
ROICexcg growth 3Y-8.59%
ROICexcg growth 5YN/A
ROICexc growth 3Y-7.46%
ROICexc growth 5YN/A
OM growth 3Y3.98%
OM growth 5YN/A
PM growth 3Y0.22%
PM growth 5YN/A
GM growth 3Y-1.12%
GM growth 5YN/A
F-Score4
Asset Turnover0.65
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.1 | ||
| Debt/FCF | 2 | ||
| Debt/EBITDA | 0.35 | ||
| Cap/Depr | 200.28% | ||
| Cap/Sales | 14.45% | ||
| Interest Coverage | 12.9 | ||
| Cash Conversion | 80.21% | ||
| Profit Quality | 34.1% | ||
| Current Ratio | 1.4 | ||
| Quick Ratio | 1.06 | ||
| Altman-Z | 4.89 |
F-Score4
WACC7.46%
ROIC/WACC1.68
Cap/Depr(3y)291.84%
Cap/Depr(5y)279.9%
Cap/Sales(3y)17.77%
Cap/Sales(5y)16.62%
Profit Quality(3y)26.98%
Profit Quality(5y)27.79%
High Growth Momentum
Growth
EPS 1Y (TTM)-1.43%
EPS 3Y14.04%
EPS 5YN/A
EPS Q2Q%-34.48%
EPS Next Y4.94%
EPS Next 2Y12.5%
EPS Next 3Y13.4%
EPS Next 5Y11.46%
Revenue 1Y (TTM)6.51%
Revenue growth 3Y13.84%
Revenue growth 5YN/A
Sales Q2Q%-1.04%
Revenue Next Year5.65%
Revenue Next 2Y8.73%
Revenue Next 3Y9.21%
Revenue Next 5Y8.44%
EBIT growth 1Y11.34%
EBIT growth 3Y18.37%
EBIT growth 5YN/A
EBIT Next Year45.94%
EBIT Next 3Y25.21%
EBIT Next 5Y17.92%
FCF growth 1Y1205.97%
FCF growth 3Y33.55%
FCF growth 5YN/A
OCF growth 1Y24.04%
OCF growth 3Y19.45%
OCF growth 5YN/A